These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 10952769

  • 1. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
    Boxenbaum H.
    J Pharm Pharm Sci; 1999; 2(2):47-52. PubMed ID: 10952769
    [Abstract] [Full Text] [Related]

  • 2. Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition.
    Boxenbaum H.
    J Pharm Pharm Sci; 1999; 2(3):89-91. PubMed ID: 10953254
    [Abstract] [Full Text] [Related]

  • 3. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.
    Baune B, Furlan V, Taburet AM, Farinotti R.
    Drug Metab Dispos; 1999 May; 27(5):565-8. PubMed ID: 10220483
    [Abstract] [Full Text] [Related]

  • 4. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
    von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI.
    J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
    [Abstract] [Full Text] [Related]

  • 5. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
    Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI.
    Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
    [Abstract] [Full Text] [Related]

  • 6. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
    Lu C, Hatsis P, Berg C, Lee FW, Balani SK.
    Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
    [Abstract] [Full Text] [Related]

  • 7. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships.
    Ervine CM, Matthew DE, Brennan B, Houston JB.
    Drug Metab Dispos; 1996 Feb; 24(2):211-5. PubMed ID: 8742233
    [Abstract] [Full Text] [Related]

  • 8. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK.
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [Abstract] [Full Text] [Related]

  • 9. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED, Walker A, Hoffer C, Sheffels P.
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [Abstract] [Full Text] [Related]

  • 10. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
    Mills BM, Zaya MJ, Walters RR, Feenstra KL, White JA, Gagne J, Locuson CW.
    Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
    [Abstract] [Full Text] [Related]

  • 11. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs.
    Kuroha M, Shirai Y, Shimoda M.
    J Vet Pharmacol Ther; 2004 Oct; 27(5):355-9. PubMed ID: 15500574
    [Abstract] [Full Text] [Related]

  • 12. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.
    Herman BD, Fleishaker JC, Brown MT.
    Clin Pharmacol Ther; 1999 Oct; 66(4):374-9. PubMed ID: 10546921
    [Abstract] [Full Text] [Related]

  • 13. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL.
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [Abstract] [Full Text] [Related]

  • 14. Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
    Wang YJ, Yu CF, Chen LC, Chen CH, Lin JK, Liang YC, Lin CH, Lin SY, Chen CF, Ho YS.
    J Cell Biochem; 2002 Feb; 87(2):147-59. PubMed ID: 12244568
    [Abstract] [Full Text] [Related]

  • 15. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T, Kivistö KT, Backman JT, Neuvonen PJ.
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [Abstract] [Full Text] [Related]

  • 16. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
    Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR.
    Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
    [Abstract] [Full Text] [Related]

  • 17. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM.
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [Abstract] [Full Text] [Related]

  • 18. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
    Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ.
    Clin Pharmacol Ther; 1995 Jul; 58(1):15-9. PubMed ID: 7628178
    [Abstract] [Full Text] [Related]

  • 19. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.
    Shayeganpour A, El-Kadi AO, Brocks DR.
    Drug Metab Dispos; 2006 Jan; 34(1):43-50. PubMed ID: 16204463
    [Abstract] [Full Text] [Related]

  • 20. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF.
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.